Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

PHASE3RecruitingINTERVENTIONAL

Enrollment

1,900

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

February 25, 2027

Study Completion Date

January 1, 2029

Conditions

Breast Cancer

Interventions

DRUG

3-year abemaciclib without chemo

aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.

DRUG

treatment of physician's choice

treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.

Trial Locations (1)

RECRUITING

Zhimin Cancer Shao, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER